EWTX Edgewise Therapeutics, Inc. Net earnings per share for the last 12 months

What are the prospects for Edgewise Therapeutics (EWTX) given the massive operating losses and the uncertainty of late-stage trials? The change in earnings per share over the last 12 months shows that the metric value is 8.20, yet biotechnology development is non-cyclical and resilient to economic phases. Ultimately, the extreme risk of unpredictable drug efficacy tests could instantaneously lead the company to insolvency.
Edgewise Corp - analytical breakdowns and key metrics (EWTX)

The development of innovative treatments for rare myopathies allows Edgewise Therapeutics (EWTX) to diversify scientific risks while creating value across pediatric and adult medicine segments. By analyzing net income per share over the last four quarters, an investor assesses the real efficiency of the business, where total annual profit is divided by the number of shares, eliminating the impact of issuance manipulations and confirming capital stability.